Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant — Stella

Home/CMV Viremia/

View on ClinicalTrials.gov

Recruiting

Back to CMV Viremia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

NYP-Weill Cornell, New York, New York

Columbia University/NYP Milstein Hospital, New York, New York

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Columbia University

Collaborators

Cornell University

Enrollment target

~150 participants

Started

September 2025

Primary completion

January 2028

Age range

18 Years – 99 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.